Literature DB >> 21458381

Cyclin E1 is amplified and overexpressed in osteosarcoma.

William W Lockwood1, Deirdre Stack, Thomas Morris, David Grehan, Conor O'Keane, Greg L Stewart, Joanna Cumiskey, Wan L Lam, Jeremy A Squire, David M Thomas, Maureen J O'Sullivan.   

Abstract

Osteosarcoma is a genetically complex malignancy, predominantly afflicting the adolescent population and associated still with relatively poor long-term outcomes. Although there has been some improvement in the understanding of osteosarcoma biology, this has not yet translated particularly well into therapeutic advances. By using a whole-genome tiling path array for comparative genomic hybridization analysis, we sought to evaluate DNA copy number changes in 22 osteosarcoma tumor samples. Regions of most frequent gains or losses generated by Genomic Identification of Significant Targets in Cancer analysis were evaluated for genes of interest. Correlation of the copy number data with preexisting expression data for these genes yielded not only targets known to be important in osteosarcoma but also novel targets, notably cyclin E1. Fluorescence in situ hybridization and immunohistochemical analysis confirmed the findings. Overexpression of cyclin E1 has potential prognostic and therapeutic implications that are discussed herein.
Copyright © 2011 American Society for Investigative Pathology and the Association for Molecular Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21458381      PMCID: PMC3077726          DOI: 10.1016/j.jmoldx.2010.11.020

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  31 in total

Review 1.  Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: osteosarcoma and related tumors.

Authors:  Avery A Sandberg; Julia A Bridge
Journal:  Cancer Genet Cytogenet       Date:  2003-08

2.  Breakpoint identification and smoothing of array comparative genomic hybridization data.

Authors:  Kees Jong; Elena Marchiori; Gerrit Meijer; A V D Vaart; Bauke Ylstra
Journal:  Bioinformatics       Date:  2004-06-16       Impact factor: 6.937

3.  Cyclin E ablation in the mouse.

Authors:  Yan Geng; Qunyan Yu; Ewa Sicinska; Manjusri Das; Jürgen E Schneider; Shoumo Bhattacharya; William M Rideout; Roderick T Bronson; Humphrey Gardner; Piotr Sicinski
Journal:  Cell       Date:  2003-08-22       Impact factor: 41.582

4.  Credentialing preclinical pediatric xenograft models using gene expression and tissue microarray analysis.

Authors:  Craig C Whiteford; Sven Bilke; Braden T Greer; Qingrong Chen; Till A Braunschweig; Nicola Cenacchi; Jun S Wei; Malcolm A Smith; Peter Houghton; Christopher Morton; C Patrick Reynolds; Richard Lock; Richard Gorlick; Chand Khanna; Carol J Thiele; Mikiko Takikita; Daniel Catchpoole; Stephen M Hewitt; Javed Khan
Journal:  Cancer Res       Date:  2007-01-01       Impact factor: 12.701

Review 5.  Life without kinase: cyclin E promotes DNA replication licensing and beyond.

Authors:  Hui Zhang
Journal:  Mol Cell       Date:  2007-01-26       Impact factor: 17.970

6.  Altered cell cycle kinetics, gene expression, and G1 restriction point regulation in Rb-deficient fibroblasts.

Authors:  R E Herrera; V P Sah; B O Williams; T P Mäkelä; R A Weinberg; T Jacks
Journal:  Mol Cell Biol       Date:  1996-05       Impact factor: 4.272

7.  Comparative genomic hybridization analysis identifies gains of 1p35 approximately p36 and chromosome 19 in osteosarcoma.

Authors:  M Zielenska; J Bayani; A Pandita; S Toledo; P Marrano; J Andrade; A Petrilli; P Thorner; P Sorensen; J A Squire
Journal:  Cancer Genet Cytogenet       Date:  2001-10-01

Review 8.  Recent advances in the management of osteosarcoma and forthcoming therapeutic strategies.

Authors:  François Lamoureux; Valérie Trichet; Céline Chipoy; Frédéric Blanchard; François Gouin; Françoise Redini
Journal:  Expert Rev Anticancer Ther       Date:  2007-02       Impact factor: 4.512

9.  DNA amplification is a ubiquitous mechanism of oncogene activation in lung and other cancers.

Authors:  W W Lockwood; R Chari; B P Coe; L Girard; C Macaulay; S Lam; A F Gazdar; J D Minna; W L Lam
Journal:  Oncogene       Date:  2008-04-07       Impact factor: 9.867

10.  Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas.

Authors:  Dariush Etemadmoghadam; Anna deFazio; Rameen Beroukhim; Craig Mermel; Joshy George; Gad Getz; Richard Tothill; Aikou Okamoto; Maria B Raeder; Paul Harnett; Stephen Lade; Lars A Akslen; Anna V Tinker; Bianca Locandro; Kathryn Alsop; Yoke-Eng Chiew; Nadia Traficante; Sian Fereday; Daryl Johnson; Stephen Fox; William Sellers; Mitsuyoshi Urashima; Helga B Salvesen; Matthew Meyerson; David Bowtell
Journal:  Clin Cancer Res       Date:  2009-02-03       Impact factor: 12.531

View more
  26 in total

1.  Toxicogenomic activity of gemcitabine in two TP53-mutated bladder cancer cell lines: special focus on cell cycle-related genes.

Authors:  Glenda Nicioli da Silva; Elaine Aparecida de Camargo; Daisy Maria Favero Salvadori
Journal:  Mol Biol Rep       Date:  2012-10-09       Impact factor: 2.316

2.  Genome-Informed Targeted Therapy for Osteosarcoma.

Authors:  Leanne C Sayles; Marcus R Breese; Amanda L Koehne; Stanley G Leung; Alex G Lee; Heng-Yi Liu; Aviv Spillinger; Avanthi T Shah; Bogdan Tanasa; Krystal Straessler; Florette K Hazard; Sheri L Spunt; Neyssa Marina; Grace E Kim; Soo-Jin Cho; Raffi S Avedian; David G Mohler; Mi-Ok Kim; Steven G DuBois; Douglas S Hawkins; E Alejandro Sweet-Cordero
Journal:  Cancer Discov       Date:  2018-09-28       Impact factor: 39.397

3.  miR-132 targeting cyclin E1 suppresses cell proliferation in osteosarcoma cells.

Authors:  Jin Wang; Guoxing Xu; Feng Shen; Yifan Kang
Journal:  Tumour Biol       Date:  2014-01-22

Review 4.  Cyclins and cyclin-dependent kinases: from biology to tumorigenesis and therapeutic opportunities.

Authors:  Mitra Zabihi; Ramin Lotfi; Amir-Mohammad Yousefi; Davood Bashash
Journal:  J Cancer Res Clin Oncol       Date:  2022-07-04       Impact factor: 4.553

Review 5.  Advances in the Treatment of Pediatric Bone Sarcomas.

Authors:  Patrick J Grohar; Katherine A Janeway; Luke D Mase; Joshua D Schiffman
Journal:  Am Soc Clin Oncol Educ Book       Date:  2017

Review 6.  Translational biology of osteosarcoma.

Authors:  Maya Kansara; Michele W Teng; Mark J Smyth; David M Thomas
Journal:  Nat Rev Cancer       Date:  2014-10-16       Impact factor: 60.716

7.  MicroRNA-874-mediated inhibition of the major G1/S phase cyclin, CCNE1, is lost in osteosarcomas.

Authors:  Tanushree Ghosh; Akhil Varshney; Praveen Kumar; Manpreet Kaur; Vipin Kumar; Ritu Shekhar; Raksha Devi; Priyanka Priyanka; Md Muntaz Khan; Sandeep Saxena
Journal:  J Biol Chem       Date:  2017-11-06       Impact factor: 5.157

8.  [Screening of cell cycle-related genes regulated by KIAA0101 in gastric cancer].

Authors:  Zhi Wang; Chengxue Dang; Rong Yan; Hao Zhang; Dawei Yuan; Kang Li
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-09-30

9.  Integrative analysis reveals relationships of genetic and epigenetic alterations in osteosarcoma.

Authors:  Stine H Kresse; Halfdan Rydbeck; Magne Skårn; Heidi M Namløs; Ana H Barragan-Polania; Anne-Marie Cleton-Jansen; Massimo Serra; Knut Liestøl; Pancras C W Hogendoorn; Eivind Hovig; Ola Myklebost; Leonardo A Meza-Zepeda
Journal:  PLoS One       Date:  2012-11-07       Impact factor: 3.240

10.  Genetically engineered mouse models and human osteosarcoma.

Authors:  Alvin Jm Ng; Anthony J Mutsaers; Emma K Baker; Carl R Walkley
Journal:  Clin Sarcoma Res       Date:  2012-10-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.